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Abstract
Purpose To compare the effect of combined oxytocin–
misoprostol versus oxytocin and misoprostol alone in
reducing blood loss at cesarean delivery.
Methods One hundred fifty patients of 18–40 years with
singleton term pregnancies scheduled for cesarean section
under spinal anesthesia were recruited in a prospective
double-blind randomized clinical trial to one of the three
following groups to receive 20 IU infusion of oxytocin
(group O), 400-lg sublingual misoprostol tablets (group
M) or 200-lg misoprostol plus 5 IU bolus intravenous
oxytocin (group MO) after delivery. The hemoglobin level
before surgery and 24 h after surgery, the need for addi-
tional oxytocic therapy, and the incidence of adverse
effects were recorded.
Results The mean blood loss during surgery was signifi-
cantly lower in group MO compared to other groups
(P = 0.04). Comparison of mean arterial pressure
(P = 0.38) and heart rate (P = 0.23) changes during spinal
anesthesia and surgery failed to reveal any statistically
significant differences between all groups through repeated
measure analysis.
Conclusion The use of combined lower dose of miso-
prostol–oxytocin significantly reduced the amount of blood
loss during and after the lower segment cesarean section
compared to higher dose of oxytocin and misoprostol alone,
and its use was not associated with any serious side effects.
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Introduction
Every day, approximately 1,000 women die from pre-
ventable causes related to pregnancy and childbirth; 99 %
of these deaths occur in low-resource countries, with more
than half occurring in Sub-Saharan Africa and one-third
occurring in South Asia [1, 2] Postpartum hemorrhage is
responsible for about a third of maternal deaths. Uterine
atony accounts for 70 % of primary postpartum hemor-
rhage and various approaches have been used for this
condition [3–5]. Nowadays, the incidence of fatal PPH has
decreased because of active management of third stage of
labor which includes controlled cord traction, uterine fun-
dal massage, and administration of a pharmacological
uterotonic [6]. Although surgeon experience has a great
role in reducing the occurrence of primary postpartum
hemorrhage at cesarean section, the administration of
uterotonics, sometimes in high doses, helps in preventing
or stopping excessive blood loss from an atonic uterus.
These include oxytocin, ergometrine, and prostaglandins.
Oxytocin and ergometrine are light- and heat-sensitive and
require cold-chain storage. Prostaglandins E2 and F2a are
used as second- or third-line agents but they are heat-labile
and too expensive for use in developing countries [7].
Misoprostol, a synthetic prostaglandin E1 analog, has been
emerged to prevent and treat gastroduodenal damage
induced by nonsteroidal anti-inflammatory drugs (NSA-
IDs) [8].
Moreover, misoprostol has been used in obstetrics and
gynecology, including medication abortion, medical man-
agement of miscarriage, induction of labor, cervical rip-
ening before surgical procedures, and the treatment of
postpartum hemorrhage. Misoprostol’s advantages over
other synthetic prostaglandin analogs are its low cost, long
half life, heat stability, and worldwide availability [9, 10].
Oxytocin is a short amino-acid polypeptide hormone,
(C43H66N12O12S2), released from the posterior lobe of the
pituitary gland [11]. It is widely used to stimulate uterine
contractions to accelerate labor progress [3]. Although
oxytocin is the gold standard drug for prevention and
treatment of PPH, it requires cool storage, sterile equip-
ment, and trained personnel, so that routine use of oxytocin
in low-resource settings may be difficult [12]. Misoprostol
offers many advantages over oxytocin in such settings. It is
heat-stable, costs lower, and has variable routes of
administration: orally, rectally, vaginally, or sublingually.
Also, it is formulated as a tablet, stable at room tempera-
ture, widely available and affordable, and does not require
any special skills, equipment, or facilities for its use [9, 12].
After oral administration, the plasma concentration
increases rapidly, peaks at 30 min, and then declines rap-
idly. The sublingual route allows fast absorption of drug
and more sustained therapeutic effect than oral adminis-
tration as it avoids first-pass effect. Misoprostol stimulates
uterine contractions by selectively binding to myometrial
prostanoid receptors, and it has a long half life and minimal
adverse effects, such as gastrointestinal symptoms, shiv-
ering, pyrexia, fatigue, and headache [7]. It is reported that
sublingual misoprostol (800 lg) is a safe and effective
treatment for women experiencing PPH [13, 14]. Regard-
ing high incidence of anemia in pregnant women, even a
small reduction of postpartum blood loss might be clini-
cally valuable and decreases patients’ distress. In general, a
synergistic effect of two agents would allow a reduction in
dose for both agents and therefore limit the side effects
while improving efficacy. We hypothesized that the com-
bined use of lower dose of oxytocin and misoprostol may
decrease the blood loss after cesarean section with minimal
side effect compared to oxytocin infusion and misopros-
tolalone..To test our hypothesis, we designed this ran-
domized double-blind, placebo-controlled study to
compare the effect of the combined use of lower dose of
oxytocin and misoprostol versus oxytocin infusion and
misoprostol alone to reduce blood loss at cesarean section.
Materials and Methods
This clinical trial was registered at the United States
National Institutes of Health (www.clinicaltrials.gov), with
the number NCT01571323. Following obtaining informed
patients consent, one hundred fifty-eight patients of
18–40 years with singleton term pregnancies undergoing
elective or emergency lower segment cesarean section
under spinal anesthesia were recruited in a prospective,
double-blinded randomized trial. The Consolidated Stan-
dards of Reporting Trials (CONSORT) recommendations
for reporting randomized, controlled clinical trials [15]
were followed (Fig. 1). Exclusion criteria included women
with any risk factor of postpartum hemorrhage i.e., anemia
(Hb8 g%), multiple gestation, antepartum hemorrhage,
poly-hydramnios, two or more previous cesarean sections
and/or a history of previous rupture uterus, current or
previous history of significant disease including heart dis-
ease, liver, renal disorders, or known coagulopathy.
Patients were randomly allocated to one of the three
groups of 50 each. The oxytocin group (group O) received
20 IU infusion of oxytocin in one liter Ringers lactate
solution at the rate of 1,000 cc/h plus one sublingual pla-
cebo tablet soon after delivery. The misoprostol group
(group M) received placebo (distilled water) in 1,000 cc
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Ringer lactate at the same rate plus 400-lg sublingual
misoprostol tablet. The combined misoprostol–oxytocin
group (group MO) received 200-lg misoprostol plus 5 IU
bolus intravenous oxytocin after delivery. The main out-
come measures were the determination of blood loss at
cesarean section, change in hemoglobin levels, need for
additional oxytocics, and drug-related side effects. The
volume of blood in the suction bottle and blood-soaked
sponges was measured. Hemoglobin values were deter-
mined both before surgery and 24 h following surgery.
Hemodynamic variables were recorded before spinal
anesthesia, 5 min spinal anesthesia, 10 and 20 min after
administration of oxytocic drugs during surgery. The need
for additional oxytocic therapy, operating time, need for
blood transfusion, side effects of study drug, and any sig-
nificant puerperal morbidity were also recorded.
Sample size estimation was based on the previous
studies which reported that the mean amount of blood loss
with the use of oxytocin during a CS is 600 cc, and
misoprostol can reduce it by 200 cc [16, 17]. Thus, con-
sidering 90 % power and 5 % error, the sample size was
determined to be 50 cases in each group. Data were ana-
lyzed using SPSS (SPSS 15.0, SPSS Inc, Chicago, II,
USA). Continuous variables were tested for normal distri-
bution by the Kolmogorov–Smirnov test. Parametric data
were expressed as mean and standard deviation (SD) and
analyzed by independent T test and Anova test. The effect
of time on the hemodynamic parameters was analyzed
using repeated measures analysis of variance test. The v2
test was used to analyze the incidence of side effects. A
P value \0.05 was considered as significant, statistically.
Results
One hundred fifty-eight patients were recruited of whom 8
excluded from the study groups due to logistical reasons or
other factors violating the study protocol (Fig. 1). There
were no significant differences between the three groups
regarding the demographic properties (age, gestational age,
and duration of surgery (Table 1). Table 2 shows the dif-
ference of volume sucked in the suction bottle after pla-
cental delivery in ml was significantly lower in MO group
(234.8 ± 92.5) than M (294.4 ± 109.01) and O
(285.74 ± 139.68) groups (P = 0.04). As shown in
Table 2, hemoglobin decreased slightly after birth in all of
three groups, but the mean decline of hemoglobin in
MO group (1.1 ± 0.08 mg/dl) was smaller than that in the
O group (1.38 ± 0.13 mg/dl) and in the M group
(1.14 ± 0.29 mg/dl). The difference of the mean decline of
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Fig. 1 Consort flow diagram
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hemoglobin between the three groups were statistically
significant (P = 0.001). The amount of additional oxytocin
requirement were not statistically significant difference
among the three groups (P [ 0.05).
As shown in Table 3, comparison of mean arterial
pressure (MAP) (P = 0.38) and heart rate (HR) (P = 0.23)
changes during spinal anesthesia and surgery failed to
reveal any statistically significant differences between all
groups through repeated measure analysis.
As shown in Table 4, no significant difference in terms
of intraoperative and postoperative side effects including
pruritus, nausea, vomiting, shivering, chest pain, and
respiratory depression were found in the three groups.
Discussion
This study demonstrated that the amount of blood loss
during and after cesarean section in the lower dose of
misoprostol–oxytocin group significantly was smaller than
oxytocin and misoprostol alone, and the use of combined
misoprostol–oxytocin was not associated with any serious
side effects. The mean decline of hemoglobin in MO group
significantly was smaller than O and M groups. We chose
to administer misoprostol sublingual route to allow fast
absorption of drug and more effective and sustained ther-
apeutic effect, although other studies presented no differ-
ence (between) buccal or sublingual misoprostol
inhemorrhage control [18–20].
In the present study, excessive postpartum hemorrhage
(more than 500 cc) occurred in 6 cases (4 %) which was
lower than what was estimated in other studies with routine
uterotonic agent administration (4–6 %) [21].
Our findings also were consistent with Derman’s study,
which reported that excessive hemorrhage occurred 12 %
in placebo group and 4.6 % in oral misoprostol group [22].
We experienced no case with more than 1,000 cc blood
loss, however, it occurred in 2 patients of Mansouri and
Table 1 Demographic data associated with the study
M O MO P value
Age(years) 27.92 ± 5.39 27.32 ± 4.3 27.42 ± 5.4 0.082
Gestational age (weeks) 37.68 ± 1.62 38.36 ± 1.72 37.94 ± 1.55 0.11
Duration of surgery(min) 38.12 ± 2.3 37.58 ± 1.72 37.1 ± 2.49 0.07
Values are presented as mean ± SD
M misoprostol, O oxytocin, MO combined misoprostol–oxytocin
Table 2 Main outcome measures
Groups P value
M MO O
Volume sucked in the suction bottle 294.4 ± 109.01 234.8 ± 92.54 285.74 ± 139.68 0.04
Hemoglobin difference (g/dl) 1.14 ± 0.29 1.1 ± 0.08 1.38 ± 0.13 \0.001
Additional oxytocin requirement 8 (16 %) 7(14 %) 7(14 %) 1
All data are expressed as mean ± SD except additional oxytocin requirement which was presented as number of patients (%)
M misoprostol, O oxytocin, MO combined misoprostol–oxytocin
Table 3 Hemodynamic changes using repeated measure analysis
Variable HR MAP
Group MO M O MO M O
5 min before SA 91.46 ± 17.48 94.63 ± 17.7 97.63 ± 16.37 84.08 ± 11.36 79.4 ± 16.58 80.76 ± 20.4
After SA 91.46 ± 16.93 95.2 ± 19.25 97.33 ± 14.1 79.14 ± 13.6 81.04 ± 15.79 76.76 ± 17.05
10 min after drug 97 ± 15.57 93.33 ± 16.42 100.66 ± 1378 79.1 ± 12.68 80.23 ± 11.41 76.64 ± 15.49
20 min after drug 96.56 ± 14.9 96.56 ± 14.9 101.26 ± 13.7 70.91 ± 13.72 75.67 ± 12.78 73.94 ± 14.7
P value 0.23 0.38
SA spinal anesthesia, HR beat per minute, MAP mean arterial pressure, M misoprostol, O oxytocin, MO combined misoprostol–oxytocin
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Alsahly study [23]. Hofmeyr et al. presented no more
efficacy for higher dose of misoprostol in preventing
hemorrhage more than 1,000 cc through a meta-analysis
[24]. However, synergistic effects of two agents would
allow a reduction in dose for both agents and therefore
limit the side effects while improving efficacy. Therefore,
use of combined lower dose of these drugs probably lead to
better control of blood loss. Maternal death rate was zero in
our trial, likewise, the need to transfusion occurred gust in
one case.
Totally 22 cases (14.6 %) required excess oxytocin
(uterotonic) in our research which was relatively the same
in all groups with no significant difference, whereas, it is
mentioned as 8.3 % in Vimala et al. study [18], 30 % in
Mansouri and Alsahly [23], and 23 % in Gerestenfeld and
Wing [25].
Regarding side effects among the groups, although
shivering, nausea, and vomiting, happened more often with
misoprostol alone, as well as which are confirmed in other
studies [19, 20], but in our study this difference was not
statistically significant. These findings are consistent with
some other researches [7, 23]. Some mentioned oxytocin-
mediated hemodynamic changes in cesarean are decreasing
blood pressure and peripheral vascular resistance plus
increasing heart rate [26, 27].
Although, due to the synergistic effect of oxytocin with
misoprostol on patients undergoing cesarean section under
spinal anesthesia, the hemodynamic changes in the MO
group were prominent, these findings were not statistically
significant and unproblematic from the clinical point of
view. The authors assumed that due to the use of lower
dose of two drugs, these hemodynamic changes were
controlled easily. Nevertheless, this is partially contrary by
WHO recommendation for PPH management, which sug-
gests that the simultaneous administration of misoprostol
with treatment doses of oxytocin is not advisable [28, 29].
However, further studies in another population and lar-
ger sample size and different dosages of drugs are required.
Conclusion
Based on the data found in our study, it was concluded that
administration of lower dose of misoprostol plus oxytocin
significantly reduced the amount of blood loss during and
after cesarean section compared to oxytocin and miso-
prostol when given alone, and use of them was not asso-
ciated with any serious side effects.
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